开放与微创肝胆胰手术后一年医疗支出及患者自付费用比较
基于IBM MarketScan商业理赔数据库(2016-2023)纳入4,552例成人肝切除或胰腺切除患者,采用逆概率加权双稳健分析比较开放与微创手术。微创手术与住院时间缩短、30天再入院率降低、一年总支出减少及误工天数减少相关,但患者自付总额无显著差异,且自付差异随保险计划类型而变化。
要点
- 微创肝胆胰手术可缩短住院2.6天并降低30天再入院风险。
- 微创手术一年总支出更低,但患者自付总额整体无明显下降。
- 自付费用差异与保险计划类型相关,限制性较强的计划中微创更省自付。
核心结论
- 微创肝胆胰手术与更低的一年总支出、更短住院、更少再入院及更少误工天数相关,但患者自付费用整体未显著降低。
研究设计与样本
- 基于IBM MarketScan Commercial Claims and Encounters数据库(2016-2023)的回顾性队列研究,纳入4,552例成人肝切除或胰腺切除患者,采用逆概率加权双稳健方法比较开放与微创手术。
主要发现
- 微创手术占26.1%(N=1,188);住院时间缩短2.6天(95%CI -3.1至-2.1);30天再入院比值比0.71(95%CI 0.58-0.88);一年总支出减少$33,255(95%CI -$46,582至-$20,789);误工天数减少6.5天(95%CI -8.4至-4.6);患者自付总额差异+$95(95%CI -$691至$1,040;P=.827);保险公司支付减少$33,627(95%CI -$48,365至-$21,593)。
关键数值与推荐
- 自付支出与保险计划类型存在交互作用(P=.019):限制性较强的计划中微创手术自付费用更低,限制性较弱的计划中未见此差异。
临床怎么用
- 向患者沟通时需说明微创手术可减少住院与误工,但自付费用节省因保险计划而异,不能一概承诺降低个人负担。
局限性
- 为商业理赔数据库回顾性分析,仅反映投保人群,误工天数由就诊记录推导,结论可能不适用于其他支付体系。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Minimally invasive surgery is increasingly adopted for hepatopancreatobiliary procedures; however, expenditure data beyond the index hospitalization remain limited, and the patient out-of-pocket burden remains unclear. We compared 1-year health care expenditures, out-of-pocket spending, utilization, and missed workdays after open versus minimally invasive hepatopancreatobiliary surgery. METHODS: Adults who underwent hepatectomy or pancreatectomy were identified from the IBM MarketScan Commercial Claims and Encounters database (2016-2023). Inverse probability of treatment weighting with a doubly robust specification was used to compare open versus minimally invasive surgery. RESULTS: Among 4,552 patients, 26.1% (N = 1,188) underwent minimally invasive surgery. Minimally invasive surgery was associated with shorter length of stay (-2.6 days; 95% confidence interval, -3.1 to -2.1), lower odds of 30-day readmission (odds ratio, 0.71; 95% confidence interval, 0.58-0.88), lower 1-year total expenditures (-$33,255; 95% confidence interval, -$46,582 to -$20,789), and fewer total missed workdays (-6.5 days; 95% confidence interval, -8.4 to -4.6). Aggregate patient out-of-pocket spending was not measurably different (+$95; 95% confidence interval, -$691 to $1,040; P = .827), whereas insurer payments were lower (-$33,627; 95% confidence interval, -$48,365 to -$21,593) following minimally invasive surgery. An interaction was observed between out-of-pocket spending and plan type (P = .019). Minimally invasive surgery was associated with lower out-of-pocket costs in more restrictive plans but not in less restrictive plans. Findings were consistent across sensitivity analyses. CONCLUSION: Minimally invasive hepatopancreatobiliary surgery was associated with lower 1-year expenditures, shorter hospitalization, fewer readmissions, and fewer encounter-derived missed workdays compared with open surgery, although cost reductions varied by procedure subtype. Aggregate patient out-of-pocket spending on covered services was not measurably lower overall, suggesting that payer-level savings do not uniformly translate into lower patient cost sharing.
引用
- Yuza K, Chatzipanagiotou OP, Angez M, et al. One-year health care expenditures and patient out-of-pocket spending after open versus minimally invasive hepatopancreatobiliary surgery. Surgery. 2026. PMID: 42398204. doi:10.1016/j.surg.2026.110391
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。